HERZLIYA, Israel and CALGARY, Alberta, Nov. 24, 2025 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled “Liposomal-synthetic-cannabidiol: preliminary translational evidence of efficacy, tolerability and pharmacokinetics following repeated subcutaneous injections in two goats” in the peer reviewed esteemed journal Frontiers in Pharmacology (https://doi.org/10.3389/fphar.2025.1689226) (1).
Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats
